Screen, Initiate, Protect (SIP) Campaign
A campaign that encourages regular screening for patients at risk of CKD and initiation of guideline-directed therapy such as Empagliflozin (Jardiance) to protect their kidneys early
Screen
CKD elevates the risk of CVD mortality when uACR>30 and/or eGFR<60
Initiate
SGLT2i is recommended as 1st line therapy in CKD according to 2024 KDIGO Guidelines
Protect
Empagliflozin (Jardiance) reduced the risk of kidney disease progression or CV death by 28% across the spectrum of uACR & eGFR
Cardio-RENAL-Metabolic
Prof. Green – How important is kidney function and albuminuria screening in people with Type 2 diabetes, and why?
Prof. Green
Prof. Jarvis – Tips on how to screen, initiate and communicate the protection of SGLT2i in T2D patients.
Prof. Jarvis
CKD at risk (T2D, HTN)
CKD
Why should medications with organ protection be initiated early for people with diabetes?
Prof. Jennifer Green
